Given the involvement of GSTs in deactivating and detoxifying carcinogens, deletions in GSTM1 and GSTT1 and IIe105Val polymorphism in GSTP1 resulting in no enzyme activity may compromise an individual’s ability to deactivate carcinogens, thus increasing risk of cancer. The gene discussed is HPGDS; the disease is cancer.